ALK mutation can be called "diamond mutation" of lung cancer, which has reached a state of long-term survival and chronic disease after successive use of targeted drugs of various generations. At present, there are first-generation crizotinib, second-generation celetinib, bugattini and aletinib as ALK targeted drugs. On July 12, official website, Certification Center (CDE) of National Pharmaceutical Products Administration (NMPA), showed that the loratinib applied for listing in Pfizer was intended to be included in the priority review, and it was intended to be used for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ALK positive, who had received one or more ALK tyrosine kinase inhibitors (TKI) in the past. The approval time is expected to be in the first quarter of 2022. This means patients who are resistant to 1 generation ALK inhibitor crizotinib, and patients who are resistant to second-generation sulitinib, aletinib, bugattinib, ensatinib, etc. There is another tough card in his hand.
Loratinib is a new, reversible and powerful inhibitor of small molecules ALK and ROS 1 developed by Pfizer, which has a strong inhibitory effect on known ALK drug-resistant mutations, so it is known as the third generation ALK inhibitor. Based on the eye-catching research data, lauritinib was approved by FDA for breakthrough treatment in 20 17, and was approved in the United States and Japan in 20 18, bringing solutions to ALK-resistant patients.